Business Wire

ContourGlobal Scales up U.S. Renewables Presence With Acquisition of 446 MWp Solar PV Portfolio From Qcells

24.1.2025 11:29:00 CET | Business Wire | Press release

Share

ContourGlobal has acquired from Qcells a portfolio of 446 MWp of solar PV projects in Colorado (WECC) and Virginia (PJM), secured with long-term high-value utility PPAsThe portfolio comprises two projects, one under construction and with near-term commercial operations, and another one in late development. Both projects have secured permits, grid connections, and procurement contracts.The projects will include solar modules manufactured at Qcells’ U.S.-based Dalton and Cartersville production facilities in Georgia. Qcells is also performing development, EPC, and O&M services as part of its total solutions provider capability.

ContourGlobal and Qcells have announced a strategic transaction for a U.S. solar PV portfolio located in Colorado and Virginia with an installed capacity of 446 MWp. This transaction expands ContourGlobal’s planned solar PV and BESS capacity in the United States to almost 1.5 GW, when combined with more than 1 GW of recently acquired projects in late development stage located in South Carolina and Arizona.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250122055737/en/

Antonio Cammisecra, CEO ContourGlobal (Photo: Business Wire)

Mr. Antonio Cammisecra, CEO of ContourGlobal, commented, “This transaction allows us to maintain momentum in our U.S. renewable growth, nearing 1.2 GW of solar PV capacity complemented with additional 0.3 GW of BESS capacity, in construction or late development. It also meaningfully accelerates the start of our commercial operations to the first half of this year. We are proud of this milestone and delighted that our partnership with Qcells will also enable us to integrate their U.S.-produced solar technology into these acquired projects.”

This latest portfolio, acquired from Qcells, is composed of two solar PV plants totalling 446 MWp and extends ContourGlobal’s renewable footprint in WECC (Western Electricity Coordinating Council) and PJM (Pennsylvania-New Jersey–Maryland) interconnection markets, providing regional diversification. The Colorado assets include 324 MWp already in construction, while the Virgina-located project of 122 MWp is expected to start construction in 2026.

Mr. IP Kim, Qcells GES President, said, “We are proud to support ContourGlobal’s US expansion. This transaction showcases Qcells’ differentiated capabilities as a ‘total energy solutions provider’ to bring projects from development into operations. We are excited to explore other opportunities where Qcells’ full suite of capabilities can deliver value to partners like ContourGlobal.”

The projects are located in attractive markets with growing demand load, paired with retirements of thermal capacity and carbon emission reduction targets at policy and corporate levels which provides opportunities for renewables development.

In particular, the Colorado assets will provide electricity to Platte River Power Authority (Platte River), a community-owned public power generation and transmission utility, under a long-term power purchase agreement. The first phase of the project, currently under construction in Northern Colorado, is a 185 MWp plant with commercial operation start estimated for the first half of 2025, and benefitting from a 22-year PPA. The second phase will bring an additional 139 MWp of capacity by 2026.

The Virgina 122 MWp project, is expected to start construction in 2026 and enter commercial operation in 2027, benefitting from a 20-year PPA with an investment grade investor-owned utility.

The total annual estimated production of the plants is more than 845 GWh, sufficient to power about 80,000 American households every year.

The agreement provides that Qcells will be responsible for the construction of the projects, which will include solar panels produced by the company at their Dalton and Cartersville facilities in Georgia. Qcells has one of the largest solar panel manufacturing facilities in the western hemisphere and, since 2019, its U.S. manufacturing capacity sits at 5.1 GW, and is expected to reach up to 8.4 GW.

Following this strategic acquisition, ContourGlobal’s total U.S. hybrid renewable capacity would reach approximately 1.5 GW - including approximately 1.2 GW of solar PV and 0.3 GW of BESS in all stages of maturity, from late development to construction. Notably, ContourGlobal also operates a 1.3 GW thermal portfolio spanning four states in the U.S.

CRC-IB served as exclusive buy-side advisor to ContourGlobal and Marathon Capital acted as exclusive financial advisor to Qcells for the transaction.

About ContourGlobal - ContourGlobal, a KKR Company, is an established Independent Power Producer (IPP) developing, acquiring and operating electricity generation and storage assets worldwide. Following the recently announced transactions, the company elevated its installed capacity under management, in late development or construction to around 7.8 GW. The footprint of the company now extends to 20 countries across Europe, Africa, Asia, North and South America. With a current share of renewables capacity of almost 50%, including capacity under construction or development, the company has committed to speed up the decarbonization of its portfolio with a sustainable transition of its thermal fleet, the repowering of existing renewable assets and the organic development of new renewable projects. ContourGlobal has gross pipeline of about 4.5 GW of development projects and a track record of 20 years of experience in partnering with communities, institutions and customers that benefit from its power supply through long-term contracts or innovative PPAs, coupled with energy management solutions.

About Qcells -Qcells USA provides complete utility-scale turnkey solutions through the entire project lifecycle from modules, solar and energy storage project development, and Engineering Procurement and Construction (EPC) services to the US utility-scale market. With a track record that includes 8.4 GW of sustainably produced module manufacturing capabilities in Georgia and nearly 2 GW of developed, constructed, and operating projects, Qcells USA is a dependable partner throughout the entire project lifecycle. Qcells USA is a flagship company of Hanwha Group, a FORTUNE Global 500 firm and a Top 7 business enterprise in South Korea. For more information, visit www.QcellsUSA.com and on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250122055737/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye